Boehringer gets EU approval for new antihypertensive drug strength

TriMed Staff | | Health Imaging | Screening

The European Commission has granted marketing authorization to Boehringer Ingelheim for a new strength of its fixed dose combination antihypertensive drug MicardisPlus 80/25 in all 27 EU member states.

The drug will be launched in Germany and Denmark in the coming weeks, followed soon by Ireland, the United Kingdom and the rest of the EU, according to the Ingelheim, Germany-based company.

The product is licensed for the treatment of hypertension in patients whose blood pressure is not adequately controlled on MicardisPlus 80/12.5 (80 mg telmisartan/12.5 mg hydrochlorothiazide) or patients, who have been previously stabilized on telmisartan and hydrochlorothiazide separately at the same dosages, the company said.

The new strength will be marketed by Boehringer in the 27 countries of the EU under the brand name MicardisPlus 80/25, and the company’s co-marketing partners will market the new drug in selected countries under its own brands. 

TriMed Staff

Related Content

Rising rates of interval breast cancers have experts calling for more risk-based screenings
Rates of breast cancer diagnosis, death expected to climb in coming decades
AI quantifies breast arterial calcifications on mammograms
AI 'not safe' to be implemented as a solo reader for breast cancer screening exams
American College of Radiology announces significant expansion of Lung Cancer Screening Registry
AI beats standard regression models at predicting lung cancer risk

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.